Continuous Glucose Monitoring (CGM) has evolved from a niche medical device category into one of the fastest-growing segments in digital health. For healthcare brands, distributors, and medical device companies, understanding CGM technology —and the manufacturing ecosystem behind it —is the first step toward entering this rapidly expanding market.
This guide covers everything you need to know: how CGM works, what drives the market, key technology differentiators, manufacturing models (OEM, SKD, ODM), and how to choose the right partner for your CGM brand.
1. What is CGM and how does it work?
A Continuous Glucose Monitor is a wearable medical device that tracks glucose levels in real time, typically measuring interstitial fluid every 1 to 15 minutes. Unlike traditional finger-prick blood glucose meters, CGM provides a continuous data stream —revealing trends, spikes, and patterns that single-point readings simply cannot capture.
The core components of a CGM system include:
- Sensor filament —A tiny enzyme-coated electrode inserted under the skin to measure glucose in interstitial fluid
- Transmitter —A wireless module that sends raw sensor data to a smartphone or dedicated reader via Bluetooth
- Adhesive patch —Medical-grade adhesive that keeps the sensor securely attached for up to 14 days
- Applicator device —A single-use insertion mechanism that places the sensor filament with minimal discomfort
- Mobile app or reader —The software interface that displays glucose readings, trends, and alerts
Modern CGM systems like the EverCheck achieve factory calibration, meaning users no longer need finger-prick calibration. The sensor is pre-calibrated during manufacturing, and the algorithm compensates for individual physiological variations over the wear period.
2. The CGM market: size, growth, and opportunity
The global CGM market was valued at approximately $6.8 billion in 2024 and is projected to reach $16.3 billion by 2032, growing at a CAGR of over 11%. Several factors are driving this growth:
- Expanding beyond diabetes —CGM is increasingly adopted by athletes, wellness consumers, and metabolic health programs, opening entirely new market segments
- Regulatory tailwinds —Reimbursement policies in the US, Europe, and parts of Asia are expanding coverage for CGM devices
- Over-the-counter availability —FDA clearance for OTC CGM devices is creating new direct-to-consumer channels
- Manufacturing maturity —The technology supply chain has matured, making it feasible for new brands to enter the market through OEM and SKD partnerships
Key insight: The fastest-growing CGM markets outside the US include Germany, Japan, Saudi Arabia, and Brazil —each with strong government healthcare procurement programs and growing diabetes prevalence. Brands that establish local manufacturing or assembly presence in these regions gain significant competitive advantages in public tenders.
3. CGM technology: what separates good sensors from great ones
Not all CGM sensors are created equal. When evaluating CGM technology —whether for distribution or OEM partnership —healthcare brands should focus on these key performance indicators:
MARD (Mean Absolute Relative Difference)
MARD is the industry-standard accuracy metric for CGM systems. It measures the average percentage difference between CGM readings and reference blood glucose values. Lower MARD = higher accuracy. Top-tier CGM systems today achieve MARD below 9%, with the EverCheck delivering MARD < 8% —competitive with leading global brands.
Sensor longevity and stability
Most modern CGM sensors are designed for 14-day wear. What matters is signal stability over those 14 days —does accuracy degrade on day 12? Quality sensors maintain consistent performance throughout the full wear period, with minimal signal drift.
Factory calibration vs. user calibration
Factory-calibrated sensors eliminate the need for finger-prick calibration, dramatically improving user experience and compliance. This requires sophisticated enzyme stabilization, membrane engineering, and manufacturing process control —areas where experienced CGM manufacturers have a significant edge.
Warm-up time
The time between sensor insertion and first glucose reading. Industry-leading systems now achieve warm-up times of under 60 minutes. Shorter warm-up = better user experience and fewer dropouts during clinical studies.
4. CGM manufacturing models: OEM vs. SKD vs. ODM
Healthcare brands entering the CGM market have three main manufacturing partnership models to choose from. Each offers different levels of control, regulatory responsibility, and speed to market.
| Model | What you receive | Regulatory responsibility | Best for |
|---|---|---|---|
| OEM | Fully finished CGM devices with your branding | Manufacturer holds certifications (CE, FDA) | Distributors, importers, brands wanting fastest entry |
| SKD | Semi-knocked-down kits for local assembly | Partner obtains local manufacturing license | Government tender bidders, local manufacturers |
| ODM | Custom-designed CGM to your specifications | Shared —depends on agreement structure | Established brands wanting proprietary technology |
For most healthcare brands entering the CGM space, OEM is the fastest path —you receive regulatory-certified, ready-to-sell products under your brand. SKD makes sense when local assembly is required for government tenders or when import duties on finished devices are prohibitively high. ODM is ideal for brands with established R&D capabilities who want to differentiate on hardware features.
5. Regulatory landscape: CE, FDA, and beyond
Regulatory compliance is the single biggest barrier to entry in the CGM market —and the strongest argument for partnering with an experienced manufacturer rather than developing technology from scratch.
CE Marking (EU)
Under the EU Medical Device Regulation (MDR) 2017/745, CGM devices are classified as Class IIb medical devices. Certification requires ISO 13485 quality management system compliance, clinical performance data, biocompatibility testing (ISO 10993), and electrical safety testing (IEC 60601).
FDA (United States)
CGM systems in the US typically follow the 510(k) premarket notification pathway, classified as Class II devices. Requirements include analytical and clinical performance validation, software documentation (IEC 62304), and cybersecurity testing.
Other key markets
- Japan (PMDA) —Requires Japan-specific clinical data or bridging studies
- Brazil (ANVISA) —BGMP certification required for manufacturing facilities
- Saudi Arabia (SFDA) —Accepts CE or FDA certification as basis for accelerated review
- Australia (TGA) —Accepts CE marking with additional Australian-specific documentation
Pro tip: When evaluating CGM manufacturing partners, ask for their Technical Documentation (TD) package —a structured collection of design specifications, risk management files, clinical evaluation reports, and test data. A well-organized TD package can reduce your local regulatory submission timeline by 3-6 months.
6. How to choose a CGM manufacturing partner
Selecting the right CGM manufacturer is arguably the most consequential decision you will make as a healthcare brand entering this market. Here are the criteria that matter most:
- Proven manufacturing scale —Can they produce millions of units annually with consistent quality? Ask about production line capacity, yield rates, and quality control infrastructure.
- Regulatory track record —Do they already hold ISO 13485 certification? Have their products been cleared by major regulatory bodies? A manufacturer with existing certifications dramatically reduces your regulatory burden.
- Sensor accuracy and clinical data —Request MARD data, clinical study reports, and real-world performance data. Don't rely on marketing claims alone.
- Supply chain stability —CGM sensors involve specialized materials (enzymes, membranes, electrodes). A manufacturer with established supplier relationships and buffer inventory is less likely to experience production interruptions.
- Technical support and documentation —Beyond the hardware, you need assembly SOPs, quality inspection standards, regulatory submission support, and ongoing technical consultation.
- Partnership flexibility —Can they support OEM, SKD, and hybrid models? Can they scale with you as your market grows? The best partnerships evolve over time.
7. The future of CGM: trends to watch
The CGM landscape is evolving rapidly. Brands that understand these emerging trends will be best positioned to capture market share:
- Non-invasive CGM —Optical and microwave-based sensing technologies are in development, though none have yet matched the accuracy of enzyme-based electrochemical sensors in clinical trials
- Multi-analyte sensing —Next-generation sensors that measure glucose, ketones, lactate, and other biomarkers simultaneously from a single wearable patch
- AI-powered insights —Machine learning algorithms that predict glucose excursions 30-60 minutes in advance, enabling proactive rather than reactive management
- Integration with closed-loop systems —CGM as the input layer for automated insulin delivery (AID) systems, creating a seamless "artificial pancreas" ecosystem
- Direct-to-consumer expansion —OTC CGM devices targeting the wellness and fitness market, projected to reach 15-20 million users by 2028
